Engineering Monodisperse Particulate Vaccines to Tailor Immunological Responses
设计单分散颗粒疫苗以定制免疫反应
基本信息
- 批准号:9337971
- 负责人:
- 金额:$ 13.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-01 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAdultAffectAnimalsAntibody ResponseAntigensAttenuatedAttenuated Live Virus VaccineBiocompatibleCategoriesChemicalsClinical TrialsCyclic GMPDengueDengue InfectionDengue VirusDevelopmentDoseElderlyEmerging Communicable DiseasesEngineeringEquilibriumFaceFerretsFilmFlavivirusFormulationGenerationsGuidelinesHumanImmune responseImmunoglobulin GIndustryInfection preventionInfluenzaInfluenza TherapeuticLearningLicensingLifeMedicalMicrobeMoldsMusNational Institute of Allergy and Infectious DiseaseNatureOnline SystemsParticle SizeParticulatePeptidesPharmaceutical PreparationsPlayProcessProductionPublic HealthSafetySerotypingShapesSubunit VaccinesTechnologyTimeTranslatingVaccinationVaccine AdjuvantVaccine DesignVaccinesViralVirusadaptive immunitybasecombatdensitydesigneconomic impactflexibilityhumanized mouseimmunogenicinfluenza virus vaccineinfluenzavirusmanufacturing processmicroorganismmouse modelnanoparticleneutralizing antibodynonhuman primatenovelparticlepathogenproduct developmentprogramsresponsescale upseasonal influenzatraffickingvaccine deliveryvaccine development
项目摘要
This project is focused on the development of a unique GMP-compliant particle molding technology that we have pioneered called PRINT� (Particle Replication in non-wetting templates) as a delivery platform for particulate multivalent vaccines targeting influenza and Dengue viruses. PRINT provides complete control over particle size, shape and chemical composition, and enables the systematic tailoring of antigen proximity to the particle, antigen density and particle size and shape to screen and identify the optimal particle parameters to elicit enhanced immunological responses. The down-selected particle parameters will provide design rules to manufacture influenza and dengue particulate multivalent vaccines to investigate the ability to generate a complete and robust neutralizing antibody response to each antigen. Also, additional Projects within our Program will utilize these multivalent particulate vaccines to address the use of novel adjuvants to modulate the immune response. These particulate vaccines will be evaluated in a humanized mouse model to determine how to prevent infection of homotypic or all 4 dengue virus serotypes. We will combine the learning from each Project to scale-up the most promising multivalent particulate vaccines and advance these to large animal challenge studies for both influenza and dengue. Due to the immediate medical need for multivalent vaccines for influenza and dengue and the cGMP-compliant nature of our particle molding technology, the formulations can be advanced into product development for human trials.
该项目的重点是开发一种独特的符合 GMP 要求的颗粒成型技术,我们首创了这种技术,称为 PRINT�(非润湿模板中的颗粒复制),作为针对流感和登革热病毒的颗粒多价疫苗的递送平台。 PRINT 可以完全控制颗粒尺寸、形状和化学成分,并能够系统地调整抗原与颗粒的接近度、抗原密度以及颗粒尺寸和形状,以筛选和识别最佳颗粒参数,从而引发增强的免疫反应。向下选择的颗粒参数将为制造流感和登革热颗粒多价疫苗提供设计规则,以研究对每种抗原产生完整且强大的中和抗体反应的能力。此外,我们计划中的其他项目将利用这些多价颗粒疫苗来解决使用新型佐剂来调节免疫反应的问题。这些颗粒疫苗将在人源化小鼠模型中进行评估,以确定如何预防同型或所有 4 种登革热病毒血清型的感染。我们将结合每个项目的经验来扩大最有前途的多价颗粒疫苗的规模,并将其推进针对流感和登革热的大型动物挑战研究。由于对流感和登革热多价疫苗的迫切医疗需求以及我们的颗粒成型技术符合 cGMP 的性质,这些配方可以进入人体试验的产品开发阶段。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jenny P Ting其他文献
Jenny P Ting的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jenny P Ting', 18)}}的其他基金
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
细胞内先天免疫受体在癌症抑制和免疫治疗中的作用
- 批准号:
10654660 - 财政年份:2019
- 资助金额:
$ 13.23万 - 项目类别:
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
细胞内先天免疫受体在癌症抑制和免疫治疗中的作用
- 批准号:
10451800 - 财政年份:2019
- 资助金额:
$ 13.23万 - 项目类别:
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
细胞内先天免疫受体在癌症抑制和免疫治疗中的作用
- 批准号:
10217045 - 财政年份:2019
- 资助金额:
$ 13.23万 - 项目类别:
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
细胞内先天免疫受体在癌症抑制和免疫治疗中的作用
- 批准号:
10019472 - 财政年份:2019
- 资助金额:
$ 13.23万 - 项目类别:
Novel Nanoparticle Platform for the delivery of Vaccines and Adjuvants
用于输送疫苗和佐剂的新型纳米颗粒平台
- 批准号:
9229872 - 财政年份:2014
- 资助金额:
$ 13.23万 - 项目类别:
Novel Nanoparticle Platform for the delivery of Vaccines and Adjuvants
用于输送疫苗和佐剂的新型纳米颗粒平台
- 批准号:
8642227 - 财政年份:2014
- 资助金额:
$ 13.23万 - 项目类别:
Discovery of New Innate Immune Pathways in Viral Recognition
病毒识别中新先天免疫途径的发现
- 批准号:
8653231 - 财政年份:2014
- 资助金额:
$ 13.23万 - 项目类别:
Novel Nanoparticle Platform for the delivery of Vaccines and Adjuvants
用于输送疫苗和佐剂的新型纳米颗粒平台
- 批准号:
9307701 - 财政年份:2014
- 资助金额:
$ 13.23万 - 项目类别:
Novel Nucleic Acid Sensing NLRs and Innate Immunity to Viruses
新型核酸传感 NLR 和病毒先天免疫
- 批准号:
9233910 - 财政年份:2014
- 资助金额:
$ 13.23万 - 项目类别:
NOD-like Receptors in Intestinal Inflammation
肠道炎症中的 NOD 样受体
- 批准号:
10447741 - 财政年份:2013
- 资助金额:
$ 13.23万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 13.23万 - 项目类别: